Search Results - "Weegink, C J"

Chronic hepatitis E after solid organ transplantation by DE NIET, A, ZAAIJER, H. L, TEN BERGE, I, WEEGINK, C. J, REESINK, H. W, BEUERS, U

“…Large outbreaks of acute hepatitis E, caused by hepatitis E virus (HEV) genotypes 1 and 2, are known from developing countries with suboptimal sanitation…”
Get full text

Randomised clinical trial: anti‐viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV by Bergmann, J. F., de Bruijne, J., Hotho, D. M., de Knegt, R. J., Boonstra, A., Weegink, C. J., van Vliet, A. A., van de Wetering, J., Fletcher, S. P., Bauman, L. A., Rahimy, M., Appleman, J. R., Freddo, J. L., Janssen, H. L. A., Reesink, H. W.

“…Aliment Pharmacol Ther 2011; 34: 443–453 Summary Background  The ANA773 is an oral prodrug of a small‐molecule toll‐like receptor (TLR)7 agonist. Preclinical…”
Get full text

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon‐alfa‐2a and ribavirin for chronic hepatitis C by de Knegt, R. J., Bezemer, G., Van Gool, A. R., Drenth, J. P. H., Hansen, B. E., Droogleever Fortuyn, H. A., Weegink, C. J., Hengeveld, M. W., Janssen, H. L. A.

“…Aliment Pharmacol Ther 2011; 34: 1306–1317 Summary Background  Treatment of hepatitis C with peginterferon and ribavirin is associated with psychiatric…”
Get full text

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir by de Niet, A., Takkenberg, R.B., Benayed, R., Riley-Gillis, B., Weegink, C.J., Zaaijer, H.L., Koot, M., Jansen, P.L.M., Beld, M.G.H.M., Lopatin, U., Reesink, H.W.

“…Abstract In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no…”
Get full text

Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients by Takkenberg, R.B., Zaaijer, H.L., Molenkamp, R., Menting, S., Terpstra, V., Weegink, C.J., Dijkgraaf, M.G.W., Jansen, P.L.M., Reesink, H.W., Beld, M.G.H.M.

“…Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) serves as a template for viral replication and plays a role in persistence of HBV infection…”
Get full text

Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir by Zaaijer, H.L, Takkenberg, R.B, Weegink, C.J, Rebers, S.P.H, Menting, S, Reesink, H.W, Schinkel, J, Molenkamp, R

“…Serial monotherapy and add-on regimes for treatment of chronic hepatitis B virus (HBV) infection may induce the accumulation of viral resistance mutations in…”
Get full text

Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-α in combination with ribavirin and amantadine: a two-arm randomized pilot study by Weegink, C. J., Sentjens, R. E., Beld, M. G., Dijkgraaf, M. G. W., Reesink, H. W.

“…Thirty‐seven chronic hepatitis C patients with virological relapse (VR) after previous interferon‐α (IFN) or IFN/ribavirin (Riba) therapy, were re‐treated…”
Get full text

Sexual transmission of hepatitis C virus by Bresters, D, Mauser-Bunschoten, E P, Reesink, H W, Roosendaal, G, van der Poel, C L, Chamuleau, R A, Jansen, P L, Weegink, C J, Cuypers, H T, Lelie, P N

“…We tested 50 heterosexual partners of hepatitis C viraemic (HCV) individuals, using second generation HCV antibody assays and a validated polymerase chain…”
Get more information

New developments in antiviral therapy for chronic hepatitis B by Takkenberg, R. B., Weegink, C. J., Zaaijer, H. L., Reesink, H. W.

“…Chronic hepatitis B affects approximately 400 million people in the world with a substantial disease burden like liver cirrhosis and hepatocellular carcinoma…”
Get full text

Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population by Zuure, F, Davidovich, U, Kok, G, Depla, A C, Hoebe, C, van den Hoek, A, Jansen, P L, van Leeuwen-Gilbert, P, Weegink, C J, Coutinho, R A, Prins, M

“…Binary file ES_Abstracts_Final_ECDC.txt matches…”
Get full text

Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor by de Bruijne, J., Thomas, X. V., Rebers, S. P., Weegink, C. J., Treitel, M. A., Hughes, E., Bergmann, J. F., de Knegt, R. J., Janssen, H. L. A., Reesink, H. W., Molenkamp, R., Schinkel, J.

“…Summary Narlaprevir, a hepatitis C virus (HCV) NS3/4A serine protease inhibitor, has demonstrated robust antiviral activity in a placebo‐controlled phase 1…”
Get full text

Evaluation of a risk assessment questionnaire to assist hepatitis C screening in the general population by Zuure, F, Davidovich, U, Kok, G, Depla, A C, Hoebe, C, van den Hoek, A, Jansen, P L, van Leeuwen-Gilbert, P, Weegink, C J, Coutinho, R A, Prins, M

“…Many individuals with hepatitis C virus (HCV) infection are undiagnosed. This study evaluates a risk assessment questionnaire, developed for use online to…”
Get full text

New developments in the antiviral treatment of hepatitis C by De Bruijne, J., Weegink, C. J., Jansen, P. L. M., Reesink, H. W.

“…Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. HCV is endemic in most parts of the world, with an…”
Get full text

Sustained Virological Response in Chronic Hepatitis C Patients after a 6- and a 36-Month Interferon-a2b Treatment Schedule. A Multicenter, Randomized, Controlled Study by M. Damen, C. J. Weegink, E. P. Mauser-Bunschoten, H. T. M. Cuypers, M.-C. Hermus, P. Sillekens, E. Haan, H. M. van den Berg, D. Bresters, P. N. Lelie, R. A. F. M. Chamuleau, H. W. Reesink

Get full text

Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin by Weegink, C J, Chamuleau, R A, Reesink, H W, Molenaar, D S

Get full text

Sustained virological response in chronic hepatitis C patients after a 6-and a 36-month interferon-α2b treatment schedule : A multicenter, randomized, controlled study by DAMEN, M, WEEGINK, C. J, CHAMULEAU, R. A. F. M, REESINK, H. W, MAUSER-BUNSCHOTEN, E. P, CUYPERS, H. T. M, HERMUS, M.-C, SILLEKENS, P, HAAN, E, VAN DEN BERG, H. M, BRESTERS, D, LELIE, P. N

Get full text

Evolutionary dynamics of hepatitis C virus NS 3 protease domain during and following treatment with narlaprevir, a potent NS 3 protease inhibitor by de Bruijne, J., Thomas, X. V., Rebers, S. P., Weegink, C. J., Treitel, M. A., Hughes, E., Bergmann, J. F., de Knegt, R. J., Janssen, H. L. A., Reesink, H. W., Molenkamp, R., Schinkel, J.

“…Summary Narlaprevir, a hepatitis C virus (HCV) NS3/4A serine protease inhibitor, has demonstrated robust antiviral activity in a placebo‐controlled phase 1…”
Get full text

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV: Randomised clinical trial: anti-viral activity of ANA773 in chronic HCV by Bergmann, J. F., de Bruijne, J., Hotho, D. M., de Knegt, R. J., Boonstra, A., Weegink, C. J., van Vliet, A. A., van de Wetering, J., Fletcher, S. P., Bauman, L. A., Rahimy, M., Appleman, J. R., Freddo, J. L., Janssen, H. L. A., Reesink, H. W.

Get full text

Hepatitis B susceptibility to lamivudine restored by resistance to adefovir by Zaaijer, H L, Takkenberg, R B, Weegink, C J, Rebers, SPH, Menting, S, Reesink, H W, Schinkel, J, Molenkamp, R

Get full text

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design by Hotho, Daphne M, de Bruijne, Joep, O'Farrell, A Marie, Boyea, Teresa, Li, Jianke, Bracken, Michele, Li, Xin, Campbell, David, Guler, Hans-Peter, Weegink, Christine J, Schinkel, Janke, Molenkamp, Richard, van de Wetering de Rooij, Jeroen, van Vliet, Andre, Janssen, Harry L A, de Knegt, Robert J, Reesink, Hendrik W

“…PHX1766 is a novel HCV NS3/4 protease inhibitor with robust potency and high selectivity in replicon studies (50% maximal effective concentration 8 nM). Two…”
Get more information